Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2019 from OUS - Molecular characterization of mesenchymal cancer development

9 publications found

Bai B, Vodák D, Nakken S, Wise JF, Blaker YN, Lingjærde OC, Brodtkorb M, Hilden V, Trøen G, Lorenz S, Lawrence MS, Myklebost O, Meza-Zepeda L, Beiske K, Hovig E, Smeland EB, Holte H, Myklebust JH (2019)
Deep Profiling of Genetic Aberrations and Clonal Evolution in Follicular Lymphoma
Blood, 134 (Supplement_1), 20
DOI 10.1182/blood-2019-128403, PubMed 31723999

Forthun RB, Hovland R, Schuster C, Puntervoll H, Brodal HP, Namløs HM, Aasheim LB, Meza-Zepeda LA, Gjertsen BT, Knappskog S, Straume O (2019)
ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
Sci Rep, 9 (1), 17471
DOI 10.1038/s41598-019-53917-5, PubMed 31767937

Goodridge JP, Jacobs B, Saetersmoen ML, Clement D, Hammer Q, Clancy T, Skarpen E, Brech A, Landskron J, Grimm C, Pfefferle A, Meza-Zepeda L, Lorenz S, Wiiger MT, Louch WE, Ask EH, Liu LL, Oei VYS, Kjällquist U, Linnarsson S, Patel S, Taskén K, Stenmark H, Malmberg KJ (2019)
Remodeling of secretory lysosomes during education tunes functional potential in NK cells
Nat Commun, 10 (1), 514
DOI 10.1038/s41467-019-08384-x, PubMed 30705279

Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O (2019)
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
Cells, 8 (2)
DOI 10.3390/cells8020189, PubMed 30795553

Hausott B, Förste A, Zach F, Mangger S, Haugsten EM, Klimaschewski L (2019)
Endocytosis and Transport of Growth Factor Receptors in Peripheral Axon Regeneration: Novel Lessons from Neurons Expressing Lysine-Deficient FGF Receptor Type 1 in vitro
Anat Rec (Hoboken), 302 (8), 1268-1275
DOI 10.1002/ar.24120, PubMed 30950230

Namløs HM, Boye K, Meza-Zepeda LA (2019)
Cell-free DNA in blood as a noninvasive insight into the sarcoma genome
Mol Aspects Med (in press)
DOI 10.1016/j.mam.2019.10.004, PubMed 31703948

Sneeggen M, Pedersen NM, Campsteijn C, Haugsten EM, Stenmark H, Schink KO (2019)
WDFY2 restrains matrix metalloproteinase secretion and cell invasion by controlling VAMP3-dependent recycling
Nat Commun, 10 (1), 2850
DOI 10.1038/s41467-019-10794-w, PubMed 31253801

Szybowska P, Kostas M, Wesche J, Wiedlocha A, Haugsten EM (2019)
Cancer Mutations in FGFR2 Prevent a Negative Feedback Loop Mediated by the ERK1/2 Pathway
Cells, 8 (6)
DOI 10.3390/cells8060518, PubMed 31146385

Zakrzewska M, Opalinski L, Haugsten EM, Otlewski J, Wiedlocha A (2019)
Crosstalk between p38 and Erk 1/2 in Downregulation of FGF1-Induced Signaling
Int J Mol Sci, 20 (8)
DOI 10.3390/ijms20081826, PubMed 31013829

 
Page visits: 277474